Roche’s revenues are likely to be flat or achieve just single-digit growth in 2022, as the boost from its COVID-19 diagnostics and therapies is expected to decline in line with a waning pandemic.
The Swiss pharma company benefitted considerably from COVID-19 revenues in the past year, with its diagnostics division increasing sales by...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?